Stock PRTC PURETECH HEALTH PLC
Add to a list
To use this feature you must be a member
Log inSign up

Ratings PureTech Health plc

Equities

PRTC

GB00BY2Z0H74

Real-time Estimate Cboe Europe
Other stock markets
 08:41:58 2024-07-16 am EDT 		5-day change 1st Jan Change
170.7 GBX -2.57% Intraday chart for PureTech Health plc -3.17% -11.84%
Jun. 25 PureTech Health Buys Back $100 Million of Shares MT
Jun. 24 EARNINGS AND TRADING: PureTech seals tender offer; HL bid questioned AN

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • For the past twelve months, EPS forecast has been revised upwards.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
PURETECH HEALTH PLC Stock PureTech Health plc
-11.84% 544M
B
MODERNA, INC. Stock Moderna, Inc.
+22.15% 46.56B
B-
LONZA GROUP AG Stock Lonza Group AG
+44.76% 41.67B
A
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-2.37% 41.16B
B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+33.84% 32.4B
B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+20.42% 28.18B
B-
CELLTRION, INC. Stock Celltrion, Inc.
-6.35% 28.1B
C
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+48.83% 14.52B
B+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+45.00% 13.74B
C+
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.06% 12.17B
B+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. PRTC Stock
  4. Ratings PureTech Health plc